Apollo Hospitals Enterprise Limited

rs,

ES 13th November 2021 The Secretary, Bombay Stock Exchange Ltd (BSE) Phiroze Jheejheebhoy Towers, Dalal Street, Mumbai - 400 001. Scrip Code - 508869 ISIN INE437A01024 Dear Sir The Secretary,

35%

Performance Q2 FY22        Q2 FY22 Consolidated Revenues of ` 37,171 mio (growth of 35% yoy). Q2 FY22 Consolidated EBITDA (Post Ind AS 116) of ` 6,150 mio. New Hospitals (excl Proton) r

65%

d PBT in Q2FY22 to the extent of ` 116 mio  Q2FY22 occupancy across the group was at 4,984 beds (65% occupancy) as compared to 4,119 beds (56% occupancy) in Q2FY21. The Key Operational Highlights Q

56%

 Q2FY22 occupancy across the group was at 4,984 beds (65% occupancy) as compared to 4,119 beds (56% occupancy) in Q2FY21. The Key Operational Highlights Q2 FY22   Q2FY22 occupancy in mature h

66%

n mature hospitals was at 3,518 beds (65% occupancy). New hospitals had an occupancy of 1,466 beds (66%) occupancy) in Q2FY22. Inpatient Volumes across the group increased by 46% from 82,153 to 120,105

46%

cupancy of 1,466 beds (66%) occupancy) in Q2FY22. Inpatient Volumes across the group increased by 46% from 82,153 to 120,105. ARPOB (excluding vaccination) was at ` 44,186 Vs ` 38,412 registering a gr

15%

,153 to 120,105. ARPOB (excluding vaccination) was at ` 44,186 Vs ` 38,412 registering a growth of 15% in H1FY22 as compared to the same period previous year. 5 5 HIGHLIGHTS Capacity  71 hospita

2 lakh

services Digital healthcare app Apollo 24/7 – agile and digitally connected to the consumer, over 2 lakh digital consults during the Quarter. 7 CONSOLIDATED FINANCIAL PERFORMANCE CONSOLIDATED FINANCI

25.5%

demerger of the Front End pharmacy, AHEL’s ownership in the wholly owned subsidiary AMPL changed to 25.5%. The assets and liabilities derecognised resulted in gain on loss of control on AMPL amounting to `

27,60737,17134.6%

h is presented under exceptional item. Q2 FY 21Q2 FY 22yoy (%)H1 FY 21H1 FY 22yoy (%)Total Revenues27,60737,17134.6%49,32274,77351.6%EBITDA (Post Ind AS 116)2,9986,150105.1%3,35311,349238.5%margin (%) 10.9%16.5%568 b

49,32274,77351.6%

der exceptional item. Q2 FY 21Q2 FY 22yoy (%)H1 FY 21H1 FY 22yoy (%)Total Revenues27,60737,17134.6%49,32274,77351.6%EBITDA (Post Ind AS 116)2,9986,150105.1%3,35311,349238.5%margin (%) 10.9%16.5%568 bps6.8%15.2%838 bp

2,9986,150105.1%

y (%)H1 FY 21H1 FY 22yoy (%)Total Revenues27,60737,17134.6%49,32274,77351.6%EBITDA (Post Ind AS 116)2,9986,150105.1%3,35311,349238.5%margin (%) 10.9%16.5%568 bps6.8%15.2%838 bpsEBIT1,5044,702212.7%2578,4953209.3%marg

“1 Heart hospital in India in Best Specialized Hospitals 2021 released by Newsweek, the premier international news magazine 6 COVID TESTING AND TREATMENT – H1FY22 1,800+ Dedicated beds 28,500 + In -Patients 2,900+ Stay I 2,77,000 + Tests 49,000 + Home care 53,00,000 + Covid Vaccine    ‘Project Stay I’ saw success with over 24,000 room nights.”

“Post external capital raise at AHL, • • • • AHEL expected to retain dominant majority shareholding in AHL; and Slump sale consideration of INR Rs 1,210 crs will be received by AHEL.”

Regd. Office

1

Notes

1

Regd. Office

19, Bishop Gardens, Raja Annamataipuram, Chennai - 600 028. General Office 'Ali Towers", Ill Floor, #55, Greams Road, Chennai - 600 006. : 044 - 28290956 / 3896 / 6681 Tel Telefax : 044 - 2829 0956 Email Website: www.apollohospitals.com : investor.reIationsapollohospitals.com EARNINGS UPDATE Q2 FY 2022 1 DISCLAIMER • No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be “forward looking statements” based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and in their opinion reasonable, including those relating to the Company’s general business plans and strateg

Notes

(1) Tamilnadu region includes Chennai hospitals, Madurai, Karur, Karaikudi, Trichy & Nellore. (2) AP, Telangana Region includes Hyderabad, Karimnagar, Vizag old, Vizag new & Kakinada. (3) Karnataka region includes Bangalore, Mysore, Jayanagar & Malleswaram. (4) Others include Bhubaneswar, Bilaspur, Nashik & Navi Mumbai. (5)Significant Hospital JVs/Subs/Associates are – Ahmedabad, Kolkata, Delhi, Indore, Assam & Lucknow (full revenues shown in table above). (6)Revenues under the head “Total” have not been provided as Consolidated actual results will differ from total due to proportionate consolidation. (7)Outpatient volume represents New Registrations only. (8)Revenues under Ind AS have been grossed up for Fixed fee Doctors & considered separately as operating cost. This was earlier being netted off from Revenues under Indian GAAP. ARPOB excludes Vaccination Revenue ParticularsH1 FY 21H1 FY 22 yoy (%)H1 FY 21H1 FY 22 yoy (%)H1 FY 21H1 FY 22 yoy (%)H1 FY 21H1 FY 22 yoy (%)H1 FY 21H1 FY 2